within Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AX02_Cyproheptadine;

model Cyproheptadine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.34,
    Cl = 3.111111111111111e-05,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.02,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0038333333333333336,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cyproheptadine</td></tr><tr><td>ATC code:</td><td>R06AX02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>20</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1600</td><td>ml/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cyproheptadine is a first-generation antihistamine with anticholinergic, antiserotonergic, and sedative properties. It is primarily used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, and conjunctivitis. It has also been used for appetite stimulation, migraine prophylaxis, and treatment of serotonin syndrome. Cyproheptadine is an approved drug and is available in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Paton, DM, &amp; Webster, DR (1985). Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). <i>Clinical pharmacokinetics</i> 10(6) 477–497. DOI:<a href=\"https://doi.org/10.2165/00003088-198510060-00002\">10.2165/00003088-198510060-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2866055/\">https://pubmed.ncbi.nlm.nih.gov/2866055</a></p></li><li><p>Peña, J, et al., &amp; Merlos, M (2008). Antihistaminic effects of rupatadine and PKPD modelling. <i>European journal of drug metabolism and pharmacokinetics</i> 33(2) 107–116. DOI:<a href=\"https://doi.org/10.1007/BF03191027\">10.1007/BF03191027</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18777946/\">https://pubmed.ncbi.nlm.nih.gov/18777946</a></p></li><li><p>Xiong, Y, et al., &amp; Liu, M (2016). CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. <i>European journal of drug metabolism and pharmacokinetics</i> 41(2) 117–124. DOI:<a href=\"https://doi.org/10.1007/s13318-014-0236-3\">10.1007/s13318-014-0236-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25427746/\">https://pubmed.ncbi.nlm.nih.gov/25427746</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R06AX02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cyproheptadine;
